John W. Park, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
John W. Park, MD

Professor of Clinical Medicine; Director of Novel Therapeutics, Breast Oncology, UCSF

Phone: (415) 353-7070 (appts)
Box 1710, UCSF
San Francisco, CA 94143-1710

UCSF Profiles | Physician Referral Directory

Cancer Center Membership

Program Member » Breast Oncology» Neurologic Oncology

Education

Harvard College, A.B., 1982, Biochemical Sciences
Stanford University School of Medicine, M.D., 1986, Medicine
University of California, Los Angeles Medical Center, 1996-1987, Internal Medicine
University of Calilfornia, Los Angeles, Residency, 1989, Internal Medicine
University of California San Francisco, Fellowship, 1992, Medical Oncology & Hematology


Professional Experience

  • 1990-1995
    Visiting Scientist, Dept. of Molecular Biology, Genentech, Inc.
  • 1992-1993
    Instructor in Medicine, Department of Medicine, Division of Hematology/Oncology, UCSF
  • 1993-2003
    Assistant Professor of Medicine, Div. of Hematology/Oncology, UCSF
  • 2003-present
    Director of Novel Therapeutics and Drug Development, Breast Oncology Program, UCSF
  • 2003-2010
    Associate Clinical Professor of Medicine & Neurosurgery, UCSF
  • 2010-present
    Professor of Clinical Medicine; Director of Novel Therapeutics, Breast Oncology

Honors & Awards

  • 1977
    National Merit Scholar
  • 1983
    cum laude in Biochemical Sciences, Harvard College
  • 1984
    Stanford Alumni Medical Student Scholar
  • 1992-1993
    Revlon-UCLA Research Fellowship
  • 1993-1994
    Young Investigator Award, American Society of Clinical Oncology (ASCO)
  • 1994-1998
    Career Development Award, Department of Defense Breast Cancer Research Program

Selected Publications

  1. Melisko ME, Goldman ME, Hwang J, De Luca A, Fang S, Esserman LJ, Chien AJ, Park JW, Rugo HS. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2016 Nov 10.
    View on PubMed
  2. Lee JS, Magbanua MJ, Park JW. Circulating tumor cells in breast cancer: applications in personalized medicine. Breast Cancer Res Treat. 2016 Dec; 160(3):411-424.
    View on PubMed
  3. Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 Jul 7; 375(1):11-22.
    View on PubMed
  4. Lee JS, Melisko ME, Magbanua MJ, Kablanian AT, Scott JH, Rugo HS, Park JW. Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer. Breast Cancer Res Treat. 2015 Nov; 154(2):339-49.
    View on PubMed
  5. Magbanua MJ, Pugia M, Lee JS, Jabon M, Wang V, Gubens M, Marfurt K, Pence J, Sidhu H, Uzgiris A, Rugo HS, Park JW. A Novel Strategy for Detection and Enumeration of Circulating Rare Cell Populations in Metastatic Cancer Patients Using Automated Microfluidic Filtration and Multiplex Immunoassay. PLoS One. 2015; 10(10):e0141166.
    View on PubMed
  6. Magbanua MJ, Das R, Polavarapu P, Park JW. Approaches to isolation and molecular characterization of disseminated tumor cells. Oncotarget. 2015 Oct 13; 6(31):30715-29.
    View on PubMed
  7. Magbanua MJ, Wolf DM, Yau C, Davis SE, Crothers J, Au A, Haqq CM, Livasy C, Rugo HS. Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response. Breast Cancer Res. 2015; 17:73.
    View on PubMed
  8. Kelley RK, Magbanua MJ, Butler TM, Collisson EA, Hwang J, Sidiropoulos N, Evason K, McWhirter RM, Hameed B, Wayne EM, Yao FY, Venook AP, Park JW. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls. BMC Cancer. 2015; 15:206.
    View on PubMed
  9. Magbanua MJ, Carey LA, DeLuca A, Hwang J, Scott JH, Rimawi MF, Mayer EL, Marcom PK, Liu MC, Esteva FJ, Park JW, Rugo HS. Circulating tumor cell analysis in metastatic triple-negative breast cancers. Clin Cancer Res. 2015 Mar 1; 21(5):1098-105.
    View on PubMed
  10. Lang JE, Scott JH, Wolf DM, Novak P, Punj V, Magbanua MJ, Zhu W, Mineyev N, Haqq CM, Crothers JR, Esserman LJ, Tripathy D, van 't Veer L, Park JW. Expression profiling of circulating tumor cells in metastatic breast cancer. Breast Cancer Res Treat. 2015 Jan; 149(1):121-31.
    View on PubMed
  11. Magbanua MJ, Park JW. Advances in genomic characterization of circulating tumor cells. Cancer Metastasis Rev. 2014 Sep; 33(2-3):757-69.
    View on PubMed
  12. Paszek MJ, DuFort CC, Rossier O, Bainer R, Mouw JK, Godula K, Hudak JE, Lakins JN, Wijekoon AC, Cassereau L, Rubashkin MG, Magbanua MJ, Thorn KS, Davidson MW, Rugo HS, Park JW, Hammer DA, Giannone G, Bertozzi CR, Weaver VM. The cancer glycocalyx mechanically primes integrin-mediated growth and survival. Nature. 2014 Jul 17; 511(7509):319-25.
    View on PubMed
  13. Magbanua MJ, Roy R, Sosa EV, Hauranieh L, Kablanian A, Eisenbud LE, Ryazantsev A, Au A, Scott JH, Melisko M, Park JW. Genome-wide copy number analysis of cerebrospinal fluid tumor cells and their corresponding archival primary tumors. Genom Data. 2014 Dec; 2:60-2.
    View on PubMed
  14. Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, Auerback G, Khanafshar E, Ordovas K, Koch KM, Moasser MM. Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. J Clin Oncol. 2014 May 10; 32(14):1472-9.
    View on PubMed
  15. Noble CO, Krauze MT, Drummond DC, Forsayeth J, Hayes ME, Beyer J, Hadaczek P, Berger MS, Kirpotin DB, Bankiewicz KS, Park JW. Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors. Nanomedicine (Lond). 2014 Jul; 9(14):2099-108.
    View on PubMed
  16. Magbanua MJ, Melisko M, Roy R, Sosa EV, Hauranieh L, Kablanian A, Eisenbud LE, Ryazantsev A, Au A, Scott JH, Park JW. Molecular profiling of tumor cells in cerebrospinal fluid and matched primary tumors from metastatic breast cancer patients with leptomeningeal carcinomatosis. Cancer Res. 2013 Dec 1; 73(23):7134-43.
    View on PubMed
  17. Magbanua MJ, Park JW. Isolation of circulating tumor cells by immunomagnetic enrichment and fluorescence-activated cell sorting (IE/FACS) for molecular profiling. Methods. 2013 Dec 1; 64(2):114-8.
    View on PubMed
  18. Weng KC, Hashizume R, Noble CO, Serwer LP, Drummond DC, Kirpotin DB, Kuwabara AM, Chao LX, Chen FF, James CD, Park JW. Convection-enhanced delivery of targeted quantum dot-immunoliposome hybrid nanoparticles to intracranial brain tumor models. Nanomedicine (Lond). 2013 Dec; 8(12):1913-25.
    View on PubMed
  19. DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman L. Developing safety criteria for introducing new agents into neoadjuvant trials. Clin Cancer Res. 2013 Jun 1; 19(11):2817-23.
    View on PubMed
  20. Magbanua MJ, Sosa EV, Roy R, Eisenbud LE, Scott JH, Olshen A, Pinkel D, Rugo HS, Park JW. Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients. Cancer Res. 2013 Jan 1; 73(1):30-40.
    View on PubMed

Go to UCSF Profiles, powered by CTSI